Health Care & Life Sciences » Pharmaceuticals | Jiangsu Hengrui Medicine Co. Ltd.

Jiangsu Hengrui Medicine Co. Ltd. A | Mutual Funds

Mutual Funds that own Jiangsu Hengrui Medicine Co. Ltd. A

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Oppenheimer Developing Markets Fund
103,499,943
2.83%
0
2.73%
02/28/2018
Government Pension Fund - Global (The)
21,177,105
0.57%
-17,152,542
0.02%
12/31/2017
UBS (Lux) Inst. SICAV II - China A Opportunity
9,215,395
0.25%
346,892
10.93%
01/31/2018
Emerging Markets Fund of the Genesis Group Trust for Employee
9,014,694
0.25%
0
1.03%
12/31/2016
Schroder ISF - Asian Opportunities
8,584,691
0.23%
-1
1.28%
05/31/2018
First State Global Umbrella Fd. Plc - China Growth Fund
8,165,537
0.22%
-1,972,880
1.82%
09/30/2017
American Funds New World Fund
7,934,108
0.22%
7,934,108
0.23%
06/30/2018
China AMC Return Fund
6,556,276
0.18%
-585,009
4.22%
12/31/2017
6,418,643
0.18%
-3,092,248
13.51%
12/31/2017
6,289,332
0.17%
6,289,332
2.47%
09/06/2017

About Jiangsu Hengrui Medicine Co.

View Profile
Address
No. 7 Kunlunshan Road
Lianyungang Jiangsu 222000
China
Employees -
Website http://www.hrs.com.cn
Updated 07/08/2019
Jiangsu Hengrui Medicine Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. Its products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; film and gel.